RARE DISEASERESEARCH ATLAS

ORPHA:79097

Folinic acid-responsive seizures

high confidenceDisorder

Publications

58

39.6th percentile

Trials

0

Interventional, condition-specific

Researchers

259

Distinct authors in sample

Gene link

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Folinic acid-responsive is a very rare epileptic disorder characterized clinically by myoclonic and clonic, or clonic associated with apnea occurring several hours to 5 days after birth and responding to folinic acid.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

Folinic acid responsive seizures

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    58 matched papers (27 in last 10 years) Source

  3. Phenotype characterisedPresent

    38 HPO annotations (e.g. Seizure; Decreased CSF 5-methyltetrahydrofolate concentration; Atypical behavior) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

38

Associated phenotypes · MONDO:0019197

  • Seizure
  • Decreased CSF 5-methyltetrahydrofolate concentration
  • Atypical behavior
  • Autistic behavior
  • Elevated CSF neopterin level

Showing 5 of 38 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

58

58 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

58 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

27 in the last 10 years · high confidence · 39.6th percentile (publications denominator)

Phrase hits: 58 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

259

Distinct author names in 58 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Brocker C3 papers · 2014

    Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, Colorado, United States of America.

    Papers in Europe PMC
  2. 02
    De Lonlay P3 papers · 2025

    Reference Center of Inherited Metabolic Diseases, Necker-Enfants-Malades University Hospital, APHP and University of Paris Cité, Institut Imagine, Filière G2M, MetabERN, Paris, France.

    Papers in Europe PMC
  3. 03
    Hyland K3 papers · 2009

    Baylor Research Institute, Metabolic Disease Center, Dallas, Texas 75226, USA.

    Papers in Europe PMC
  4. 04
    Jakobs C3 papers · 2011
    Papers in Europe PMC
  5. 05
    Nabbout R3 papers · 2025

    Reference Center for Rare Epilepsies, Department of Pediatric Neurology, Necker Enfants Malades University Hospital, APHP, ERN EPICARE, and University Paris Cité, Paris, France.

    Papers in Europe PMC
  6. 06
    Scharer G3 papers · 2011

    Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA.

    Papers in Europe PMC
  7. 07
    Sharma S3 papers · 2025

    Department of Pediatrics, Lady Hardinge Medical College, New Delhi 110001, India. sharma.suvasini@gmail.com.

    Papers in Europe PMC
  8. 08
    Tabarki B3 papers · 2024

    Service de neuropédiatrie, département de pédiatrie, hôpital Militaire, P.O Box 7897, Riyadh 11159, Arabie saoudite. Electronic address: btabarki@hotmail.com.

    Papers in Europe PMC
  9. 09
    Van Hove JL3 papers · 2011
    Papers in Europe PMC
  10. 10
    Vasiliou V3 papers · 2014

    Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Denver, Aurora, Colorado, United States of America.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

high confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Folinic acid-responsive seizures — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Folinic acid-responsive seizures" OR "Folinic acid responsive seizures"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Folinic acid-responsive seizures" OR "Folinic acid responsive seizures"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T01:56:20.919Z